WePlay apoia o desenvolvimento do futebol de base no Brasil em parceria com o Craque do Amanhã

BRASÍLIA, Brasil, July 05, 2026 (GLOBE NEWSWIRE) — O WePlay, aplicativo de entretenimento social voltado para jovens usuários em todo o mundo e conhecido por sua proposta de experiências interativas e descontraídas, anunciou recentemente uma doação de US$ 4.990 ao projeto socioeducativo brasileiro Craque do Amanhã. A contribuição foi feita pela empresa responsável pelo aplicativo, … Read more

WePlay Supports Craque do Amanhã to Advance Youth Football Education in Brazil

BRASILIA, Brazil, July 05, 2026 (GLOBE NEWSWIRE) — WePlay, a global social entertainment platform built around lightweight interactive experiences for young users, announced that its operating company, WEJOY PTE. LTD., has donated US$4,990 to Craque do Amanhã, a Brazilian educational and socio-sports project. The donation will support the purchase of sports equipment for the project’s … Read more

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages PicS N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PICS

NEW YORK, July 05, 2026 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Class A common stock of PicS N.V. (NASDAQ: PICS) pursuant and/or traceable to PicS N.V.’s January 30, 2026 initial public offering (the “IPO”). A class action lawsuit … Read more

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, July 05, 2026 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public. Source: globenewswire Country: United … Read more

Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formu

ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting three validated targets of amylin receptor, GLP-1R and GIPR. ASC36_35 FDC demonstrated approximately 51% greater relative body weight… Source: prnewswire Country: United States